HHC
INO icon

Hutchin Hill Capital’s Inovio Pharmaceuticals INO Stock Holding History

Hutchin Hill Capital’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$55K Buy
+1,100
New +$68.2K 0.02% 365

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hutchin Hill Capital's INO Position: Q4 2017 in Review

Hutchin Hill Capital opened a new position in Inovio Pharmaceuticals (INO) in Q4 2017: 1,100 shares worth $55K. The stake represents 0.02% of the portfolio and ranks #365 among its holdings.

133 funds tracked by Wall St. Rank hold INO as of Q4 2017.

  • Hutchin Hill Capital held 1,100 shares of Inovio Pharmaceuticals worth $55K as of Q4 2017.
  • Inovio Pharmaceuticals was a new Hutchin Hill Capital position in Q4 2017.
  • Inovio Pharmaceuticals made up 0.02% of Hutchin Hill Capital's portfolio in Q4 2017, its #365 holding.
  • 133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.